SomaLogic Provides 2022 Revenue Guidance in Conjunction with Analyst and Investor Meeting

3 years ago

BOULDER, Colo., Feb. 04, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, will host a…

Revolo Biotherapeutics Receives MHRA Approval for Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in the United Kingdom

3 years ago

Company to initiate one Phase 2 trial in rheumatoid arthritis and a second Phase 2 trial in uveitisNEW ORLEANS and…

Surgery Partners, Inc. Announces Fourth Quarter 2021 Earnings Release Date and Conference Call Details

3 years ago

BRENTWOOD, Tenn., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical…

Cytokinetics Announces FDA Acceptance of New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure With Reduced Ejection Fraction

3 years ago

PDUFA Target Action Date Set for November 30, 2022 FDA is Currently Not Planning to Hold an Advisory Committee Meeting to…

MedMira Provides a Pre-Annual General Meeting Update

3 years ago

HALIFAX, Nova Scotia, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides a pre-Annual General Meeting…

IRADIMED CORPORATION Announces Fourth Quarter 2021 Financial Results

3 years ago

Reports fourth quarter 2021 revenue of $11.9 million, GAAP diluted EPS of $0.31 and non-GAAP diluted EPS of $0.33Announces full-year…

FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference

3 years ago

SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer,…

Algernon Pharmaceuticals Announces Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

3 years ago

VANCOUVER, British Columbia, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB:…

Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome

3 years ago

NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage…

Immunovant Reports Financial Results for the Quarter Ended December 31, 2021

3 years ago

Company Ended the Quarter With Cash of Approximately $527.0 MillionNEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq:…